Postnatal oral hydrocortisone in treatment of bronchopulmonary dysplasia: an observational study
The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia. This prospective pilot study was conducted in a tertiary referral neonatal intensive care unit placed in Ankara Zekai Tahir Burak Materni...
Saved in:
Published in | Tüberküloz ve toraks Vol. 61; no. 3; pp. 245 - 249 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Turkey
01.01.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia.
This prospective pilot study was conducted in a tertiary referral neonatal intensive care unit placed in Ankara Zekai Tahir Burak Maternity Teaching Hospital. Preterm babies (> 32 week gestational age or > 1500 g birth weight) who were ventilator dependent approximately at or beyond three weeks of age (defined as rescue treatment) or were oxygen dependent on postmenstrual 36th week without evidence of any infection (defined as bronchopulmonary dysplasia treatment) were enrolled in the study. Hydrocortisone was used orally in an initial dose of 1 mg/kg twice a daily for a week and then the dose was tapered by 10-20% every other day regarding to clinical response.
A total of 90 infants were enrolled in this study. After hydrocortisone treatment only 3 (3.4%) patients were still on respiratory support. When safety of the drug was evaluated 8 (8.8%) infants had early complications of hydrocortisone treatment.
To the best of our knowledge this study is the first trial in the literature along with the hydrocortisone dose and the initiation time in treatment of bronchopulmonary displasia. |
---|---|
AbstractList | INTRODUCTIONThe aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia. MATERIALS AND METHODSThis prospective pilot study was conducted in a tertiary referral neonatal intensive care unit placed in Ankara Zekai Tahir Burak Maternity Teaching Hospital. Preterm babies (> 32 week gestational age or > 1500 g birth weight) who were ventilator dependent approximately at or beyond three weeks of age (defined as rescue treatment) or were oxygen dependent on postmenstrual 36th week without evidence of any infection (defined as bronchopulmonary dysplasia treatment) were enrolled in the study. Hydrocortisone was used orally in an initial dose of 1 mg/kg twice a daily for a week and then the dose was tapered by 10-20% every other day regarding to clinical response. RESULTSA total of 90 infants were enrolled in this study. After hydrocortisone treatment only 3 (3.4%) patients were still on respiratory support. When safety of the drug was evaluated 8 (8.8%) infants had early complications of hydrocortisone treatment. CONCLUSIONTo the best of our knowledge this study is the first trial in the literature along with the hydrocortisone dose and the initiation time in treatment of bronchopulmonary displasia. The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary dysplasia. This prospective pilot study was conducted in a tertiary referral neonatal intensive care unit placed in Ankara Zekai Tahir Burak Maternity Teaching Hospital. Preterm babies (> 32 week gestational age or > 1500 g birth weight) who were ventilator dependent approximately at or beyond three weeks of age (defined as rescue treatment) or were oxygen dependent on postmenstrual 36th week without evidence of any infection (defined as bronchopulmonary dysplasia treatment) were enrolled in the study. Hydrocortisone was used orally in an initial dose of 1 mg/kg twice a daily for a week and then the dose was tapered by 10-20% every other day regarding to clinical response. A total of 90 infants were enrolled in this study. After hydrocortisone treatment only 3 (3.4%) patients were still on respiratory support. When safety of the drug was evaluated 8 (8.8%) infants had early complications of hydrocortisone treatment. To the best of our knowledge this study is the first trial in the literature along with the hydrocortisone dose and the initiation time in treatment of bronchopulmonary displasia. |
Author | Eraslan, Zeynep Erdeve, Ömer Mutlu, Banu Sandal, Gonca Dilmen, Uğur Kanmaz, Gözde Oğuz, Şerife Suna |
Author_xml | – sequence: 1 givenname: Banu surname: Mutlu fullname: Mutlu, Banu email: kocabasgonca@mynet.com organization: Neonatal Intensive Care Unit, Ankara Dr. Zekai Tahir Burak Woman Health and Diseases Training and Research Hospital, Ankara, Turkey. kocabasgonca@mynet.com – sequence: 2 givenname: Gonca surname: Sandal fullname: Sandal, Gonca – sequence: 3 givenname: Gözde surname: Kanmaz fullname: Kanmaz, Gözde – sequence: 4 givenname: Zeynep surname: Eraslan fullname: Eraslan, Zeynep – sequence: 5 givenname: Ömer surname: Erdeve fullname: Erdeve, Ömer – sequence: 6 givenname: Şerife Suna surname: Oğuz fullname: Oğuz, Şerife Suna – sequence: 7 givenname: Uğur surname: Dilmen fullname: Dilmen, Uğur |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24298974$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kMtOwzAQRb0oog8Qf4C8g03K-JXE7FBVHlIlWMA6OI6jBiV2sB2k_D2pWtjMSHOPrjRniWbWWYPQFYG1EFl-F-OaQ5rO0AK45AlhGZujZQhfACInnJ2jOeVU5jLjC_T55kK0KqoWOz-N_Vh5p52PTZhacWNx9EbFztiIXY1L76zeu35oO2eVH3E1hr5VoVH3WFnsymD8j4rNFLY4xKEaL9BZrdpgLk97hT4et--b52T3-vSyedglmkIak6wSVJWGMA2CmUqnimX1dIPcSJ5rBkJlNUiSMa1kqcuSVjIFCXlNDVCl2QrdHnt7774HE2LRNUGbtlXWuCEUhKeC5ABUTOjNEdXeheBNXfS-6aZvCgLFQWERY3FQOJHXp9Kh7Ez1z_35Y79QQnJI |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.5578/tt.4066 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 249 |
ExternalDocumentID | 10_5578_tt_4066 24298974 |
Genre | Journal Article |
GroupedDBID | 123 53G ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF DIK EBD ECM EIF EMB EMOBN EOJEC F5P GJB GX1 NPM OBODZ OK1 PGMZT RNS RPM SV3 XSB AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c206t-7d52abe13c053edc6a37fd5208e948c305a7f09173ca9bcbb2d960908f2e02ac3 |
ISSN | 0494-1373 |
IngestDate | Fri Jun 28 17:28:42 EDT 2024 Fri Aug 23 02:35:21 EDT 2024 Sat Sep 28 08:02:17 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c206t-7d52abe13c053edc6a37fd5208e948c305a7f09173ca9bcbb2d960908f2e02ac3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.5578/tt.4066 |
PMID | 24298974 |
PQID | 1465180025 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_1465180025 crossref_primary_10_5578_tt_4066 pubmed_primary_24298974 |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Turkey |
PublicationPlace_xml | – name: Turkey |
PublicationTitle | Tüberküloz ve toraks |
PublicationTitleAlternate | Tuberk Toraks |
PublicationYear | 2013 |
SSID | ssj0058143 |
Score | 1.906149 |
Snippet | The aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for bronchopulmonary... INTRODUCTIONThe aim of our study was to determine whether hydrocortisone even at low dose could be an effective and safe alternative treatment for... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 245 |
SubjectTerms | Administration, Oral Bronchopulmonary Dysplasia - drug therapy Dose-Response Relationship, Drug Female Humans Hydrocortisone - therapeutic use Infant, Newborn Infant, Premature Male Pilot Projects Prospective Studies Treatment Outcome |
Title | Postnatal oral hydrocortisone in treatment of bronchopulmonary dysplasia: an observational study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24298974 https://search.proquest.com/docview/1465180025 |
Volume | 61 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviHEtMGQk9oQykjiJHd6ybjBB2wdopWovwXYcgTYlVZdMan89x3bqtdUQl5fIsuLE8vl0bj4XhN5KyvyyLAuPqIJ6EY25J4gkXigIZUqXOxH6Rnc0Ts6m0edZPOv1rjeiltpGHMnVrXkl_0NVmAO66izZf6Cs-yhMwBjoC0-gMDz_isa6025l2n-YPPsfywLEUa37K9e2GMhNGDnohGJRV8Ds5u0lbFAHyxXLq7nJojQZz6A3CueiNVkk68Kzne46aQ8Hg0PGhFpcdMPLevXuWjffWPALp5yPppPh1N5lVK3z4GTjk2xovPCwCycLvmTjUXZupvWV_XGyKhzSTr9m34aZCUM4V8tKzTc9FLpbhPNQWEYWpZEXENuyZM11k2ADXWSThdrykp00Dm1B011GHwOjAeo0zREoJLeU0t4RcS7wEEwevTRvmlwvvIPuhjSNdSjop5kLDYpZYKMt1_u2ydZ64fvuj9tazG9ME6OiTB6iB51tgTMLlH3UU9UjdG_URU88Rt8dXrDGC97GC_5ZYYcXXJd4Fy_Y4eUD5hXeQgs2aHmCph9PJ4Mzr-uw4cnQTxqPFnHIhQqIBF6sCplwQkuY85lKIyZBFnBagkZJieSpkEKEha5Q6LMyVH7IJXmK9irY4XOEJVXC5wxW-mkU-VJXNiQgHWiiGJOS9OGV7sTyuS2kku9Qo4_erE8yByanb654per2StuncaBNm7iPntkjdh8BHTNlYBW_-PMPXqL7N_h8hfaaRasOQKdsxGsDgF9NanoC |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Postnatal+oral+hydrocortisone+in+treatment+of+bronchopulmonary+dysplasia%3A+an+observational+study&rft.jtitle=Tu%CC%88berku%CC%88loz+ve+toraks&rft.au=MUTLU%2C+Banu&rft.au=SANDAL%2C+Gonca&rft.au=KANMAZ%2C+G%C3%B6zde&rft.au=ERASLAN%2C+Zeynep&rft.date=2013-01-01&rft.issn=0494-1373&rft.volume=61&rft.issue=3&rft.spage=245&rft.epage=249&rft_id=info:doi/10.5578%2Ftt.4066&rft.externalDBID=n%2Fa&rft.externalDocID=10_5578_tt_4066 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0494-1373&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0494-1373&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0494-1373&client=summon |